Découvrez l’impact de l’astate-211 sur le cancer de la vessie · En savoir plus
Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053/j.semnuclmed.2025.09.005
Watabe, T.; Mukai, K.; Naka, S.; Sasaki, H.; Kamiya, T.; Hayakawa, T.; Fukuhara, A.; Takano, T.; Shirakami, Y.; Ooe, K.; Shigeno, S.; Okamura, S.; Masumura, K.; Hida, E.; Haba, H.; Toyoshima, A.; Isohashi, K.; Shimomura, I.; Tomiyama, N. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of Nuclear Medicine 2025. – DOI: 10.2967/jnumed.125.270810
ClinicalTrials.gov ID: NCT03670966 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03670966
ClinicalTrials.gov ID: NCT03128034 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03128034
Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. Journal of Nuclear Medicine 2008;49(1):30-38. DOI: 10.2967/jnumed.107.046938